



News Release

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, Ronald Trahan Associates, +1-508-816-6730, rtrahan@ronaldtrahan.com

CorInnova Selected to Present at TCT 2017 “Shark Tank” Competition

Company Is Developing EpicHeart™, A Less-Invasive, Non-Blood-Contacting Soft Robotic Heart Device to Treat Heart Failure (HF)

HOUSTON, Oct. 27, 2017—[CorInnova](#) Inc., an emerging medical device company developing novel technology for the treatment of Heart Failure, announced today that it has been selected to present at the 29th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium. CorInnova’s presentation will be on Tuesday, Oct. 31, at 9:16 a.m. MST.

[CLICK HERE TO SEE HOW THE CORINNOVA “EpicHeart™” SOFT ROBOTIC HEART ASSIST DEVICE IS DELIVERED MINIMALLY INVASIVELY](#)

“We are very excited to be presenting our EpicHeart™ technology at the TCT 2017 Shark Tank competition. With the first minimally invasively delivered, collapsible and self-expanding thin film soft robotic device for cardiac assist that does not touch the blood, we believe EpicHeart™ is going to lead to a new paradigm for heart failure treatment,” said **William Altman**, CEO of CorInnova.

About CorInnova Technology

CorInnova has developed a direct cardiac compression device designed to be a significant break with the prior art. CorInnova’s biventricular device is a collapsible thin-film pneumatically actuated soft robotic device that surrounds both ventricles of the heart. Air inflates the device in synchrony with the heart and increases cardiac output by gently squeezing the heart. CorInnova has also developed an innovative collapsible self-expanding device design that simplifies and speeds implantation. Due to the minimally invasive technology, hospital stays could potentially be reduced from 30 days to 4 to 6 days, compared to LVADs, and overall adverse events compared to LVADs could be reduced up to 30 to 40%. CorInnova’s device can potentially be used for a range of end-stage heart failure patients for cardiac assist, ranging from short-term “Bridge to Decision” use, medium-term “Bridge to Transplant” use, and all the way to permanent “Destination

Therapy” use. Diastolic as well as systolic heart failure patients may benefit from the technology. Diastolic heart failure patients currently have no approved device treatment.

About CorInnova Inc.

CorInnova is a medical device company founded to commercialize technology developed by the Cardiac Mechanics Laboratory of Dr. John C. Criscione, Professor in the Department of Biomedical Engineering at Texas A&M University. The company has been supported by the UK-based Wellcome Trust, a group of private investors, federal institutions including the NIH National Heart Lung Blood Institute (NHLBI) and National Science Foundation (NSF), and the Texas Emerging Technology Fund. The company is headquartered in Houston at Johnson & Johnson Innovation JLABS at Texas Medical Center (JLABS @ TMC). For more information, please visit www.corinnova.com.

CAUTION: The CorInnova technology EpicHeart™ is not approved for human use.

#####